Abstract. The targeting protein for the Xenopus kinesin-like protein 2 (TPX2), a microtubule-associated protein, has been utilized as a tool to evaluate, more precisely, the proliferative behavior of tumor cells. The abnormal expression of TPX2 in a variety of malignant tumor types has been reported, however less is known about its role in cervical cancer. In the present study, the association between TPX2 expression and the biological behavior of cervical cancer, was investigated. Immunohistochemistry and RT-PCR were used to detect the expression of TPX2 in cervical cancer tissues. The inhibitory effect of TPX2-siRNA on the growth of SiHa human cervical carcinoma cells was studied in vitro. TPX2 expression was identified as significantly higher in cervical carcinoma compared with the control, normal cervical tissues. TPX2 siRNA transfected into SiHa cells induced apoptosis and inhibited cell proliferation and invasion. Similar results were obtained by in vivo transplantation, as TPX2 siRNA transfection significantly reduced tumor growth of the xenograft in nude mice. The results demonstrated that TPX2 is important in the regulation of tumor growth in cervical cancer and therefore may be a potential therapeutic target as a novel treatment strategy.
Introduction
Targeting protein for Xenopus kinesin-like protein 2 (TPX2) is a microtubule-associated protein. It is one of the best-known factors regulated by the RanGTP gradient and has a functional role in mitosis. The appearance and subsequent expression of TPX2 is mediated by the cell cycle, emerging at G1-S stage and diminishing following the completion of cytokinesis (1) .
In recent studies, it has been revealed that TPX2 is overexpressed in various carcinoma tissue types, including lung (2), breast (3) and salivary gland cancer (4) . In this study, it was demonstrated that the overexpression of TPX2 in tumor cells caused exuberant amplification of the centrosome, developed aneuploidy and transformation, promotion of tumor proliferation and differentiation, as well as downregulation of tumor apoptosis (2) (3) (4) (5) (6) . Conversely, it has also been demonstrated that inhibiting TPX2 and its associated pathways in tumor cells, leads to cancer cell apoptosis. This provides evidence that TPX2 may be a potential therapeutic candidate for the development of novel pharmacological cancer treatments (5, 7, 8) .
One recent study suggested that TPX2 may also be expressed in cervical carcinoma (8) , however the exact function of TPX2 in cervical cancer formation and regulation remains elusive. In the present study, the expression of TPX2 in cervical carcinoma in human patients and the human cervical cancer cell line SiHa cells was examined. Gene-silencing methods were utilized to specifically knock-down TPX2 expression in vitro and in vivo, to advance the understanding of the regulatory mechanisms of TPX2 in cervical cancer development. Our results may provide invaluable experimental data, to facilitate in the diagnosis and treatment of cervical cancer in the future.
Materials and methods
Clinical sample preparation. The specimens of cervical cancer tissues were collected from 52 patients at The China-Japan Union Hospital of Jilin University from May 2011-October 2012, which were immediately cryopreserved in liquid nitrogen and stored at -80˚C. The cervical cancer patients' age was between 36-64 years (mean, 50.4±4.3) and the paraffin blocks of cervical samples were obtained. The normal tissue group had 24 specimens collected from the tissues of total hysterectomy due to myoma of the uterus and the patients' age range was 30-61 years (mean, 47.8±5.5). All patients provided informed consent and the experimental procedures were reviewed and approved by the Ethics Committee of the China-Japan Union Hospital of Jilin University (Changchun, Jilin, China). Western blotting. Whole-cell collection was conducted by RIPA buffer [50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate and 1% Nadeoxycholate (pH 7.4)] supplemented with a protease inhibitor. Protein concentrations were then measured using Bio-Rad protein assay kits (Bio-Rad, Hercules, CA, USA). Then, the protein lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes (Hybond™-P; Amersham Biosciences, Piscataway, NJ, USA), blocked by PBS containing 0.2% Tween-20 and 5% non fat dry milk, incubated with primary antibody and then with horseradish peroxidaselabeled secondary antibody. The signals were then detected by X-ray film.
RT-PCR.
Apoptosis assay. Following 24-72 h in culture, 1x10 6 of the gastric cancer cells were washed twice with PBS and then resuspended in binding buffer (10 mM HEPES/NaOH, 140 mM NaCl, 2.5 mM CaCl 2 ). FITC-Annexin V (Becton-Dickinson, Franklin Lakes, NJ, USA) was added at a final concentration of 1 mg/ml Annexin V and then 10 mg/ml PI was added. The mixture was incubated for 10 min in the dark at room temperature and then measured by a FACScan using Cellquest software (Becton-Dickinson).
Cell proliferation assay. Cells were plated at a concentration of 2.5x10 4 cells/ml of culture medium in 96-well plates. After 24, 48 and 72 h, the number of viable cells was determined in triplicate wells using an MTT assay (Sigma, St. Louis, MO, USA) according to the manufacturer's instructions.
Matrigel invasion assay. Migration assay was performed using a quantitative cell migration assay kit (ECM500; Chemicon, Temecula, CA, USA) according to the manufacturer's instructions. Warm serum-free medium (200 ml) was added to the ECM layer and allowed to hydrate for 1-2 h at room temperature. Cells were dislodged following a brief trypsinization and dispersed into a homogeneous single-cell suspension that was washed and resuspended in serum-free medium at 5x10 5 cells/ml. Aliquots (200 ml) of cell suspension were allowed to adhere to the surface for 1 h at 37˚C. The migration medium (500 µl) containing cyclopamine was then added to the bottom chamber. Following 24 h incubation at 37˚C, with 5% CO 2 in the air, cells in the upper chamber were stained for 20 min and dissolved in 10% acetic acid and the optical density (OD) was read at 560 nm on a standard microplate reader. 10 mM stock solution) to give a total body concentration of 100 µM, followed by tumor extraction and immediate examination under light microscope (Nikon Eclipse E600; Nikon, Tokyo, Japan).
Results

TPX2 expression in cervical cancer tissues in vivo and in vitro.
The mRNA and protein expression of TPX2 in pathological and normal cervical tissues were examined by RT-PCR and western blotting (Fig. 1) . The results revealed that TPX2 mRNA and protein expression increased in cervical squamous cell carcinoma in vivo and cervical cancer cell line SiHa and HeLa cells in vitro. By contrast, there were weak/undetectable levels of TPX2 expression in normal cervical epithelium tissues in vivo.
TPX2 knockdown induces apoptosis in SiHa cells.
SiHa cells were either transfected with 50 nM scrambled siRNA or 50 nM TPX2-siRNA for 24-72 h. The cells were then harvested and the apoptosis rates were analyzed using flow cytometry (Fig. 2) . The results demonstrated that the cells treated with TPX2 silencing exhibited significantly higher apoptosis rates, at 24 and 72 h, compared with the rate of the cells treated with the negative control siRNA.
TPX2 silencing inhibits cervical cancer proliferation. SiHa cells were either untransfected (control), transfected with 50 nM scrambled siRNA or transfected with 50 nM TPX2 siRNA. Cells in the three groups were then harvested at 24, 48, and 72 h following transfection. The proliferation rate of SiHa cells was significantly lower in the TPX2-siRNA group compared with the control group and negative siRNA group ( * P<0.01; Fig. 3 ). There was no statistically significant difference between the control group and negative siRNA group (P>0.05).
TPX2 silencing slows cervical cancer cell migration. SiHa cells were either untransfected (control), transfected with 50 nM scrambled siRNA or transfected with 50 nM TPX2 siRNA. The invasive capacity of SiHa cells was examined by a Matrigel invasion assay (Fig. 4) . The results revealed that SiHa cells migrated significantly slower while transfected with TPX2-siRNA (P<0.05; Fig. 4B ). By contrast, there was no statistical difference between the untransfected SiHa cells and the cells transfected with negative control siRNA (P>0.05).
TPX2 silencing reduces cervical tumor growth in vivo.
Finally, we investigated whether the inhibitory effect of silencing TPX2 on cancer cell growth/migration in vitro would persist in vivo. Initially, SiHa cells were either untransfected (control), transfected with 50 nM scrambled siRNA or transfected with 50 nM TPX2 siRNA. Following this, the three groups of cells were injected into nude mice and the in vivo tumor growth one month after xenograft was examined. The results demonstrated that the TPX2 silencing significant reduced the growth of cervical tumor in nude mice (Fig. 5) .
Discussion
TPX2 is a microtubule-associated protein that is important in the regulation of the cell cycle and mitosis, and functions in RanGTP-dependent manner (9, 10) . Through cell mitosis, TPX2 interacts with downstream genes and proteins to locolize Aurora A to the microtubules of the mitotic spindle, and to induce Aurora A phosphorylation through an active structure (1, 11) . In cancer biology, TPX2 was initially recognized as an oncogene factor amplified from chromosome 20q11.2 (12) . Several studies have demonstrated that TPX2-induced tumor proliferation and inhibition of apoptosis, was upregulated in various tumorous tissue types, including lung, ovarian, pancreatic, breast and oral cancer (2, 3, 6, (13) (14) (15) (16) (17) (18) (19) (20) .
In the present study, we demonstrated that TPX2 was expressed in cervical cancer carcinoma tissues in vivo and HeLa and SiHa cervical cancer cell lines in vitro, but not in the normal cervical epithelium tissues. TPX2 expression was then silenced in SiHa cells and it was revealed that this knockdown induced apoptosis, inhibited cell proliferation and slowed invasion. These results are consistent with previous studies that have demonstrated TPX2 actively regulated tumor growth in other cancer tissues (21, 22) . Finally, in vivo tests were conducted and xenografted cervical tumors in nude mice were significantly reduced with TPX2 silencing.
To conclude, the results have suggested that TPX2 may become a new biomarker for cervical cancer diagnostics, and A B is a target that has potential for facilitating the development of more efficacious therapeutic methods to treat patients with cervical cancer.
